<p>Apellis Pharmaceuticals, Inc.（纳斯达克代码：APLS - 获取免费报告）在周五的交易中股价上涨了 6.2%。该股票最高交易价为 23.08 美元，最后交易价为 23.5760 美元。在交易中大约有 222,080 股易手，较日均成交量 2,352,329 股下降了 91%。该股票此前收盘价为 22.19 美元。</p>
<h2>分析师评级调整</h2>
<ul>
<li>Beam Therapeutics 因基因治疗许可支付而大幅上涨</li>
</ul>
<p>几位研究分析师对该公司发表了看法。富国银行于 10 月 15 日星期三发布研究报告，开始对 Apellis Pharmaceuticals 进行覆盖。他们给予该股票 “增持” 评级，目标价为 32.00 美元。HC Wainwright 在 10 月 31 日星期五的报告中将 Apellis Pharmaceuticals 的目标价从 57.00 美元下调至 45.00 美元，并给予该公司 “买入” 评级。Wolfe Research 于 11 月 6 日星期四发布研究报告，开始对 Apellis Pharmaceuticals 的股票进行覆盖。他们对该股票给予 “同行表现” 评级。华尔街 Zen 在 11 月 8 日星期六的研究报告中将 Apellis Pharmaceuticals 的股票评级从 “持有” 上调至 “买入”。最后，瑞穗证券在 11 月 3 日星期一的研究报告中将 Apellis Pharmaceuticals 的目标价从 24.00 美元下调至 19.00 美元，并给予该公司 “中性” 评级。九位研究分析师对该股票给予 “买入” 评级，七位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，共识目标价为 33.06 美元。</p>
<p><strong>查看我们对 APLS 的最新分析</strong></p>
<h2>Apellis Pharmaceuticals 价格表现</h2>
<ul>
<li>小型股是否预示市场下跌？</li>
</ul>
<p>该股票的 50 日移动平均价格为 22.89 美元，200 日移动平均价格为 22.07 美元。该公司的债务与股本比率为 0.90，速动比率为 3.10，流动比率为 3.54。该公司的市值为 30.1 亿美元，市盈率为 76.92，贝塔值为 0.37。</p>
<p>Apellis Pharmaceuticals（纳斯达克代码：APLS - 获取免费报告）于 10 月 30 日星期四发布了季度财报。该公司报告季度每股收益为 1.67 美元，超出分析师一致预期的 1.03 美元，超出幅度为 0.64 美元。Apellis Pharmaceuticals 的净利润率为 4.43%，股本回报率为 18.94%。该公司季度收入为 4.5858 亿美元，而一致预期为 3.6458 亿美元。去年同期，该公司的每股收益为（0.46）美元。该公司的收入同比增长了 133.0%。整体来看，股票分析师预测 Apellis Pharmaceuticals, Inc.在当前财年将发布-1.7 美元的每股收益。</p>
<h2>内部人士买卖</h2>
<p>在其他 Apellis Pharmaceuticals 的新闻中，董事 A. Sinclair Dunlop 于 10 月 10 日星期五出售了 31,092 股该公司的股票。该股票以平均价格 23.72 美元出售，总交易额为 737,502.24 美元。出售后，该董事直接持有该公司 3,837 股，价值约 91,013.64 美元。此次交易使其持股减少了 89.01%。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，首席财务官 Timothy Eugene Sullivan 于 10 月 21 日星期二出售了 10,000 股该公司的股票。该股票以平均价格 28.03 美元出售，总价值为 280,300.00 美元。出售完成后，首席财务官直接持有该公司 110,936 股，价值为 3,109,536.08 美元。此次交易使其持股减少了 8.27%。该交易的披露信息可在 SEC 文件中找到。内部人士在上个季度共出售了 87,373 股公司股票，价值 2,084,036 美元。公司内部人士持有公司股票的 6.50%。</p>
<h2>机构投资者对 Apellis Pharmaceuticals 的看法</h2>
<p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。Corton Capital Inc.在第二季度收购了 Apellis Pharmaceuticals 的新头寸，价值约 364,000 美元。Woodline Partners LP 在第一季度增加了对 Apellis Pharmaceuticals 股票的持股，增幅为 15.5%。Woodline Partners LP 现在持有 218,850 股该公司的股票，价值 4,786,000 美元，此前在上个季度又购买了 29,373 股。Wealth Enhancement Advisory Services LLC 在第二季度增加了对 Apellis Pharmaceuticals 股票的持股，增幅为 43.5%。Wealth Enhancement Advisory Services LLC 现在持有 100,666 股该公司的股票，价值 1,838,000 美元，此前在上个季度又购买了 30,507 股。Bayforest Capital Ltd 在第一季度增加了对 Apellis Pharmaceuticals 股票的持股，增幅为 431.9%。Bayforest Capital Ltd 现在持有 52,338 股该公司的股票，价值 1,145,000 美元，此前在上个季度又购买了 42,499 股。最后，Pallas Capital Advisors LLC 在第二季度增加了对 Apellis Pharmaceuticals 股票的持股，增幅为 29.0%。Pallas Capital Advisors LLC 现在持有 54,849 股该公司的股票，价值 949,000 美元，此前在上个季度又购买了 12,315 股。目前 96.29% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Apellis Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Apellis Pharmaceuticals, Inc.是一家商业阶段的生物制药公司，专注于通过抑制补体系统来发现、开发和商业化治疗自身免疫和炎症疾病的化合物。它提供 EMPAVELI 用于治疗阵发性夜间血红蛋白尿、C3 肾小管病和免疫复合物膜增生性肾小管炎，以及与造血干细胞移植相关的血栓性微血管病；并提供 SYFOVRE 用于治疗与年龄相关的黄斑变性和地理性萎缩（GA）引起的地理性萎缩。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Apellis Pharmaceuticals 更好的股票</li>
<li>上海证券交易所综合指数是什么？</li>
<li>Kroger 股票分析：数字转型、股息安全性与 2026 年增长计划</li>
<li>科技股解析：你需要了解的科技知识</li>
<li>加密矿工会转向人工智能吗？三大关键参与者的最新动态</li>
<li>什么是盈利惊喜？</li>
<li>Salesforce 股票像弹簧一样蓄势待发，准备反弹</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Apellis Pharmaceuticals 吗？</h2>
<p>在你考虑 Apellis Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Apellis Pharmaceuticals 并不在名单上。</p>
<p>虽然 Apellis Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

APLS

<p>Apellis Pharmaceuticals（纳斯达克代码：APLS）股票上涨 6.2%，至 23.5760 美元，交易量显著低于平均水平。分析师的评级不一，普遍目标价为 33.06 美元。最近的内部交易包括董事 Dunlop 和首席财务官 Sullivan 的出售。机构投资者已调整其持仓，Woodline Partners 和 Wealth Enhancement Advisory Services 的增持尤为显著。公司报告了强劲的季度收益，收入同比增长 133%</p>

<p>Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) shares were up 6.2% during trading on Friday . The stock traded as high as $23.08 and last traded at $23.5760. Approximately 222,080 shares changed hands during trading, a decline of 91% from the average daily volume of 2,352,329 shares. The stock had previously closed at $22.19.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.（纳斯达克代码：APLS - 获取免费报告）在周五的交易中股价上涨了 6.2%。该股票最高交易价为 23.08 美元，最后交易价为 23.5760 美元。在交易中大约有 222,080 股易手，较日均成交量 2,352,329 股下降了 91%。该股票此前收盘价为 22.19 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治疗许可支付而大幅上涨</li>
</ul>
</div><p>Several research analysts have weighed in on the company. Wells Fargo &amp; Company began coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 15th. They issued an &#34;overweight&#34; rating and a $32.00 target price on the stock. HC Wainwright decreased their price target on Apellis Pharmaceuticals from $57.00 to $45.00 and set a &#34;buy&#34; rating for the company in a report on Friday, October 31st. Wolfe Research started coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, November 6th. They issued a &#34;peer perform&#34; rating on the stock. Wall Street Zen upgraded shares of Apellis Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, November 8th. Finally, Mizuho reduced their target price on shares of Apellis Pharmaceuticals from $24.00 to $19.00 and set a &#34;neutral&#34; rating for the company in a research note on Monday, November 3rd. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of &#34;Hold&#34; and a consensus target price of $33.06.</p>
<div class="lb-trans"><p>几位研究分析师对该公司发表了看法。富国银行于 10 月 15 日星期三发布研究报告，开始对 Apellis Pharmaceuticals 进行覆盖。他们给予该股票 “增持” 评级，目标价为 32.00 美元。HC Wainwright 在 10 月 31 日星期五的报告中将 Apellis Pharmaceuticals 的目标价从 57.00 美元下调至 45.00 美元，并给予该公司 “买入” 评级。Wolfe Research 于 11 月 6 日星期四发布研究报告，开始对 Apellis Pharmaceuticals 的股票进行覆盖。他们对该股票给予 “同行表现” 评级。华尔街 Zen 在 11 月 8 日星期六的研究报告中将 Apellis Pharmaceuticals 的股票评级从 “持有” 上调至 “买入”。最后，瑞穗证券在 11 月 3 日星期一的研究报告中将 Apellis Pharmaceuticals 的目标价从 24.00 美元下调至 19.00 美元，并给予该公司 “中性” 评级。九位研究分析师对该股票给予 “买入” 评级，七位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，共识目标价为 33.06 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on APLS</strong></p>
<div class="lb-trans"><p><strong>查看我们对 APLS 的最新分析</strong></p>
</div><h2>Apellis Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 价格表现</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否预示市场下跌？</li>
</ul>
</div><p>The stock's fifty day moving average price is $22.89 and its 200-day moving average price is $22.07. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The firm has a market cap of $3.01 billion, a PE ratio of 76.92 and a beta of 0.37.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均价格为 22.89 美元，200 日移动平均价格为 22.07 美元。该公司的债务与股本比率为 0.90，速动比率为 3.10，流动比率为 3.54。该公司的市值为 30.1 亿美元，市盈率为 76.92，贝塔值为 0.37。</p>
</div><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Thursday, October 30th. The company reported $1.67 EPS for the quarter, topping analysts' consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The firm had revenue of $458.58 million for the quarter, compared to the consensus estimate of $364.58 million. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. The firm's revenue was up 133.0% on a year-over-year basis. As a group, equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals（纳斯达克代码：APLS - 获取免费报告）于 10 月 30 日星期四发布了季度财报。该公司报告季度每股收益为 1.67 美元，超出分析师一致预期的 1.03 美元，超出幅度为 0.64 美元。Apellis Pharmaceuticals 的净利润率为 4.43%，股本回报率为 18.94%。该公司季度收入为 4.5858 亿美元，而一致预期为 3.6458 亿美元。去年同期，该公司的每股收益为（0.46）美元。该公司的收入同比增长了 133.0%。整体来看，股票分析师预测 Apellis Pharmaceuticals, Inc.在当前财年将发布-1.7 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 31,092 shares of the business's stock in a transaction on Friday, October 10th. The stock was sold at an average price of $23.72, for a total transaction of $737,502.24. Following the sale, the director directly owned 3,837 shares in the company, valued at approximately $91,013.64. The trade was a 89.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CFO Timothy Eugene Sullivan sold 10,000 shares of the company's stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $28.03, for a total value of $280,300.00. Following the completion of the sale, the chief financial officer directly owned 110,936 shares in the company, valued at $3,109,536.08. This trade represents a 8.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 87,373 shares of company stock worth $2,084,036 in the last quarter. Company insiders own 6.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Apellis Pharmaceuticals 的新闻中，董事 A. Sinclair Dunlop 于 10 月 10 日星期五出售了 31,092 股该公司的股票。该股票以平均价格 23.72 美元出售，总交易额为 737,502.24 美元。出售后，该董事直接持有该公司 3,837 股，价值约 91,013.64 美元。此次交易使其持股减少了 89.01%。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，首席财务官 Timothy Eugene Sullivan 于 10 月 21 日星期二出售了 10,000 股该公司的股票。该股票以平均价格 28.03 美元出售，总价值为 280,300.00 美元。出售完成后，首席财务官直接持有该公司 110,936 股，价值为 3,109,536.08 美元。此次交易使其持股减少了 8.27%。该交易的披露信息可在 SEC 文件中找到。内部人士在上个季度共出售了 87,373 股公司股票，价值 2,084,036 美元。公司内部人士持有公司股票的 6.50%。</p>
</div><h2>Institutional Investors Weigh In On Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Apellis Pharmaceuticals 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the business. Corton Capital Inc. acquired a new position in Apellis Pharmaceuticals during the second quarter worth about $364,000. Woodline Partners LP increased its stake in shares of Apellis Pharmaceuticals by 15.5% during the 1st quarter. Woodline Partners LP now owns 218,850 shares of the company's stock worth $4,786,000 after purchasing an additional 29,373 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Apellis Pharmaceuticals by 43.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 100,666 shares of the company's stock worth $1,838,000 after purchasing an additional 30,507 shares in the last quarter. Bayforest Capital Ltd raised its position in shares of Apellis Pharmaceuticals by 431.9% during the 1st quarter. Bayforest Capital Ltd now owns 52,338 shares of the company's stock worth $1,145,000 after purchasing an additional 42,499 shares during the last quarter. Finally, Pallas Capital Advisors LLC raised its position in shares of Apellis Pharmaceuticals by 29.0% during the 2nd quarter. Pallas Capital Advisors LLC now owns 54,849 shares of the company's stock worth $949,000 after purchasing an additional 12,315 shares during the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。Corton Capital Inc.在第二季度收购了 Apellis Pharmaceuticals 的新头寸，价值约 364,000 美元。Woodline Partners LP 在第一季度增加了对 Apellis Pharmaceuticals 股票的持股，增幅为 15.5%。Woodline Partners LP 现在持有 218,850 股该公司的股票，价值 4,786,000 美元，此前在上个季度又购买了 29,373 股。Wealth Enhancement Advisory Services LLC 在第二季度增加了对 Apellis Pharmaceuticals 股票的持股，增幅为 43.5%。Wealth Enhancement Advisory Services LLC 现在持有 100,666 股该公司的股票，价值 1,838,000 美元，此前在上个季度又购买了 30,507 股。Bayforest Capital Ltd 在第一季度增加了对 Apellis Pharmaceuticals 股票的持股，增幅为 431.9%。Bayforest Capital Ltd 现在持有 52,338 股该公司的股票，价值 1,145,000 美元，此前在上个季度又购买了 42,499 股。最后，Pallas Capital Advisors LLC 在第二季度增加了对 Apellis Pharmaceuticals 股票的持股，增幅为 29.0%。Pallas Capital Advisors LLC 现在持有 54,849 股该公司的股票，价值 949,000 美元，此前在上个季度又购买了 12,315 股。目前 96.29% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Apellis Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.是一家商业阶段的生物制药公司，专注于通过抑制补体系统来发现、开发和商业化治疗自身免疫和炎症疾病的化合物。它提供 EMPAVELI 用于治疗阵发性夜间血红蛋白尿、C3 肾小管病和免疫复合物膜增生性肾小管炎，以及与造血干细胞移植相关的血栓性微血管病；并提供 SYFOVRE 用于治疗与年龄相关的黄斑变性和地理性萎缩（GA）引起的地理性萎缩。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>Kroger Stock Analysis: Digital Pivot, Dividend Safety &amp; 2026 Growth Plan</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Will Crypto Miners Pivot to AI? Latest on 3 Key Players</li>
<li>What is an Earnings Surprise?</li>
<li>Salesforce Stock Is Coiled Like a Spring and Ready to Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Apellis Pharmaceuticals 更好的股票</li>
<li>上海证券交易所综合指数是什么？</li>
<li>Kroger 股票分析：数字转型、股息安全性与 2026 年增长计划</li>
<li>科技股解析：你需要了解的科技知识</li>
<li>加密矿工会转向人工智能吗？三大关键参与者的最新动态</li>
<li>什么是盈利惊喜？</li>
<li>Salesforce 股票像弹簧一样蓄势待发，准备反弹</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Apellis Pharmaceuticals 吗？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Apellis Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Apellis Pharmaceuticals 并不在名单上。</p>
</div><p>While Apellis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Apellis Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Apellis Pharmaceuticals（纳斯达克股票代码：APLS）股价上涨 6.2% - 现在是否仍然值得购买？